Stockscreener 앱 받기
10.60
1.63%
0.17
시간 외 거래:
10.60
Bioage Labs Inc 주식(BIOA)의 최신 뉴스
354,395 Shares in BioAge Labs, Inc. $BIOA Bought by Walleye Capital LLC - MarketBeat
BioAge Labs, Inc.: Shareholders Board Members Managers and Company Profile | US09077V1008 - marketscreener.com
Cormorant Asset Management (BIOA) discloses 5.38% BioAge Labs ownership stake - Stock Titan
214,546 Shares in BioAge Labs, Inc. $BIOA Purchased by Dimensional Fund Advisors LP - MarketBeat
BioAge Labs, Inc. (NASDAQ:BIOA) Receives Consensus Rating of "Moderate Buy" from Analysts - MarketBeat
Renaissance Technologies LLC Buys 120,188 Shares of BioAge Labs, Inc. $BIOA - MarketBeat
We're Not Very Worried About BioAge Labs' (NASDAQ:BIOA) Cash Burn Rate - Moomoo
BIOAGE Labs Inc (BIOA) Earnings Forecast: Future EPS & Revenue Growth Estimates - TradingKey
Analysts’ Opinions Are Mixed on These NA Stocks: BioAge Labs, Inc. (BIOA) and Fiserv (FISV) - The Globe and Mail
BIOA News & Events - Intellectia AI
BIOAGE Labs Inc (BIOA) Stock News Today - TradingKey
A Quick Look at Today's Ratings for BioAge Labs(BIOA.US), With a Forecast Between $21 to $73 - Moomoo
BioAge Labs, Inc. Stock 12‑Month Price Target Cut to $35.62, Implies 224% Upside - TradingView
BioAge Labs, Inc. (BIOA) Reports Q2 Loss, Beats Revenue Estimates - Yahoo Finance
BioAge Labs (NASDAQ:BIOA) Releases Quarterly Earnings Results, Beats Expectations By $0.07 EPS - MarketBeat
BioAge Labs, Inc. reports results for the quarter ended June 30Earnings Summary - TradingView
BioAge Labs Reports Second Quarter 2026 Financial Results and Provides Business Updates - The Manila Times
BIOA: BGE-102 clinical trials advanced, net loss increased, and cash reserves remain strong - TradingView
BioAge Labs reports Q2 2026 net loss $26.1M, cash and securities $381.3M; BGE-102 Phase 2 dosing underway - TradingView
BioAge Labs, Inc. Q2 2026: Revenue $2.45M, EPS $(0.58) — 10-Q Summary - TradingView
BioAge Labs (NASDAQ: BIOA) builds $381.3M cash buffer as BGE-102 advances - Stock Titan
BioAge Labs | 10-Q: Q2 2026 Earnings Report - Moomoo
BioAge Reports Q2 Net Loss of $26.1 Million - Quiver Quantitative
BioAge Labs, Inc. Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2026 - marketscreener.com
BioAge's BGE-102 Enters Obesity Trial; Eye Study Planned - Stock Titan
Price to earnings forward of BioAge Labs, Inc. – SWB:Y7G - TradingView
BIOA Q2'26 Earnings: revenue estimate is 1.50M USD - TradingView
Piper Sandler Maintains BioAge Labs(BIOA.US) With Buy Rating, Maintains Target Price $73 - Moomoo
BioAge Labs posts partial recovery after deep selloff, rises 19% (BIOA:NASDAQ) - Seeking Alpha
Roth MKM Maintains BioAge Labs(BIOA.US) With Buy Rating, Maintains Target Price $25 - Moomoo
Weekly Recap: ZEUS miss lifts BGE-102 and Analysts cut BIOA PTs, keep Buy - TradingView
Janus Henderson Group PLC Acquires 1,685,063 Shares of BioAge Labs, Inc. $BIOA - MarketBeat
BioAge Labs (NASDAQ:BIOA) Given Buy Rating at BTIG Research - MarketBeat
Why is BioAge Labs stock plunging today? By Investing.com - Investing.com Canada
Why is BioAge Labs stock plunging 60% today? By Investing.com - Investing.com Canada
338,654 Shares in BioAge Labs, Inc. $BIOA Acquired by Stempoint Capital LP - MarketBeat
BIOA|BIOAGE Labs Inc|Price:20.850|Chg%:-0.920 - TradingKey
BIOAGE Labs Inc (BIOA) Revenue Breakdown: Business Segments, Regional Revenue & Profit Contribution - TradingKey
BIOAGE Labs Inc (BIOA) Valuation: PE, PB & Fair Value Analysis - TradingKey
BioAge Labs, Inc. $BIOA Shares Sold by Orbimed Advisors LLC - MarketBeat
Octagon Capital Advisors LP Has $30.57 Million Stock Position in BioAge Labs, Inc. $BIOA - MarketBeat
The Gross Law Firm Notifies Shareholders of BioAge Labs, Inc.(BI - GuruFocus
BIOAGE Labs Inc (BIOA) Income Statement - TradingKey
TradingKey - TradingKey
BIOAGE Labs Inc (BIOA) Balance Sheet - TradingKey
BIOAGE Labs Inc (BIOA) Dividends & Stock Splits: Historical Payouts and Event Timeline - TradingKey
BIOAGE Labs Inc (BIOA) Shareholder Structure: Major Shareholders & Institutional Holdings - TradingKey
BIOA|BIOAGE Labs Inc|Price:10.540|Chg%:+0.060 - TradingKey
BioAge Labs, Inc. Revenue Breakdown – NASDAQ:BIOA - TradingView
BIOAGE Labs Inc (BIOA) Risk Assessment: Volatility, Financial Risk & Investment Risk - TradingKey
BioAge Labs (BIOA) price target increased by 44.67% to 44.27 - MSN
Price to earnings forward of BioAge Labs, Inc. – FWB:Y7G - TradingView
BioAge Labs, Inc. (NASDAQ:BIOA) Given Average Recommendation of "Moderate Buy" by Analysts - MarketBeat
BIOA Q1 2026 Earnings: EPS Beat Surprise but Stock Drops on Pre-Revenue StatusInterim Report - dars.gov.et
HitGen partner BioAge begins phase 2 trial of BGE-102 By Investing.com - Investing.com Nigeria
HitGen Partner BioAge Labs Doses First Participant In Phase 2 Trial Of BGE-102 - TradingView
HitGen Partner BioAge Labs Doses First Participant in Phase 2 Trial of BGE-102, a Novel Oral NLRP3 Inhibitor for Cardiovascular Risk Reduction - The Manila Times
HitGen partner BioAge begins phase 2 trial of BGE-102 - Investing.com
HitGen Partner BioAge Labs Doses First Participant in Phase 2 Trial of BGE-102, a Novel Oral NLRP3 Inhibitor for Cardiovascular Risk Reduction – Company AnnouncementFT.com - Financial Times
Price to book forward of BioAge Labs, Inc. – DUS:Y7G - TradingView
BioAge Labs, Inc. begins Phase 2 trial for obesity and cardiovascular risk treatment - Traders Union
How Broad Russell Growth Index Inclusion Could Shape BioAge Labs (BIOA) Investor Exposure - simplywall.st
BioAge Labs: Buy Rating Reiterated on NLRP3 Pathway Validation Potential; $50 Price Target Maintained - TipRanks
Needham Maintains BioAge Labs(BIOA.US) With Buy Rating, Maintains Target Price $50 - Moomoo
BioAge advances inflammaging drug into Phase 2 - Longevity.Technology
Price to sales forward of BioAge Labs, Inc. – NASDAQ:BIOA - TradingView
Enterprise value to EBITDA forward of BioAge Labs, Inc. – DUS:Y7G - TradingView
BIOA Final Opportunity to Lead BioAge Labs, Inc. Securities Frau - GuruFocus
0.79%
5.15%
자본화:
|
볼륨(24시간):